<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2805257488
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZYTEDIN 100MG POWDER FOR INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AZACITIDINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1041.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="THYMOORGAN PHARMAZIE GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            THYMOORGAN PHARMAZIE GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BC07 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Zytedin is</strong></p><p>Zytedin is an anti-cancer agent which belongs to a group of medicines called &lsquo;anti-metabolites&rsquo;. Zytedin contains the active substance &lsquo;azacitidine&rsquo;.</p><p><strong>What Zytedin is used for</strong></p><p>Zytedin is used in adults who are not able to have a stem cell transplantation to treat:</p><ul><li>Higher-risk myelodysplastic syndromes (MDS).</li><li>Chronic myelomonocytic leukaemia (CMML).</li><li>Acute myeloid leukaemia (AML).</li></ul><p>These are diseases which affect the bone marrow and can cause problems with normal blood cell production.</p><p><strong>How Zytedin works</strong></p><p>Zytedin works by preventing cancer cells from growing. Azacitidine becomes incorporated into the genetic material of cells (ribonucleic acid (RNA) and deoxyribonucleic acid (DNA)). It is thought to work by altering the way the cell turns genes on and off and also by interfering with the production of new RNA and DNA. These actions are thought to correct problems with the maturation and growth of young blood cells in the bone marrow that cause myelodysplastic disorders, and to kill cancerous cells in leukaemia.</p><p>Talk to your doctor or nurse if you have any questions about how Zytedin works or why this medicine has been prescribed for you</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Zytedin &nbsp;</strong></p><ul><li>If you are allergic to azacitidine or any of the other ingredients of this medicine (listed in section 6).</li><li>If you have advanced liver cancer.</li><li>If you are breast-feeding.</li></ul><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before using Zytedin:</p><ul><li>If you have decreased counts of platelets, red or white blood cells.</li><li>If you have kidney disease.</li><li>If you have liver disease.</li><li>If you have ever had a heart condition or heart attack or any history of lung disease.</li></ul><p>Vidaza can cause a serious immune reaction called `differentiation syndrome&#39; (see section 4).</p><p><em>Blood test</em></p><p>You will have blood tests before you begin treatment with Zytedin and at the start of each period of treatment (called a &lsquo;cycle&rsquo;). This is to check that you have enough blood cells and that your liver and kidneys are working properly.</p><p><strong>Children and adolescents</strong></p><p>Zytedin is not recommended for use in children and adolescents below the age of 18.</p><p><strong>Other medicines and Zytedin</strong></p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. This is because Zytedin may affect the way some other medicines work. Also, some other medicines may affect the way Zytedin works.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><em>Pregnancy</em></p><p>You should not use Zytedin during pregnancy as it may be harmful to the baby.</p><p>If you are a woman who can become pregnant you should use an effective method of contraception while taking Zytedin and for 6 months after stopping treatment with Zytedin.</p><p>Tell your doctor straight away if you become pregnant during treatment.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><em>Breast-feeding</em></p><p>You should not breast-feed when using azacitidine. It is not known if this medicine passes into human milk.</p><p><em>Fertility</em></p><p>Men should not father a child while receiving treatment with Zytedin. Men should use an effective method of contraception while taking Zytedin and for 3 months after stopping treatment with Zytedin.</p><p>Talk to your doctor if you wish to conserve your sperm before starting this treatment.</p><p><strong>Driving and using machines </strong></p><p>Do not drive or use any tools or machines if you experience side effects, such as tiredness</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Before giving you Zytedin, your doctor will give you another medicine to prevent nausea and vomiting at the start of each treatment cycle.</p><ul><li>The recommended dose is 75 mg per m<sup>2</sup> body surface area. Your doctor will decide your dose of this medicine, depending on your general condition, height and weight. Your doctor will check your progress and may change your dose if necessary.</li><li>Zytedin is given every day for one week. This &ldquo;treatment cycle&rdquo; will be repeated every 4 weeks. You will usually receive 4 - 6 treatment cycles.</li></ul><p>This medicine will be given to you as an injection under the skin (subcutaneously) or as infusion (intravenously) by a doctor or nurse. It may be given under the skin on your thigh, tummy or upper arm.</p><p>For further information about the dosage, please see section &ldquo;The following information is intended for healthcare professionals only&rdquo;.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor straight away if you notice any of the following side effects:</p><ul><li>Drowsiness, shaking, jaundice, abdominal bloating and easy bruising. These may be symptoms of liver failure and can be life-threatening.</li><li>Swelling of the legs and feet, back pain, reduced passing of water, increased thirst, rapid pulse, dizziness and nausea, vomiting or reduced appetite and feelings of confusion, restlessness or fatigue. These may be symptoms of kidney failure and can be life-threatening.</li><li>A fever. This could be due to an infection as a result of having low levels of white blood cells, which can be life-threatening.</li><li>Chest pain or shortness of breath which may be accompanied with a fever. This may be due to an infection of the lung called &ldquo;pneumonia&rdquo;, and can be life-threatening.</li><li>Bleeding. Such as blood in the stools due to bleeding in the stomach or gut, or such as bleeding inside your head. These may be symptoms of having low levels of platelets in your blood.</li><li>Difficulty breathing, swelling of the lips, itching or rash. This may be due to an allergic (hypersensitivity) reaction.</li></ul><p><strong><em>Other side effects include:</em></strong></p><p><strong>Very common side effects (may affect more than 1 in 10 people)</strong></p><ul><li>Reduced red blood count (anaemia). You may feel tired and pale.</li><li>Reduced white blood cell count. This may be accompanied by a fever. You are also more likely to get infections.</li><li>A low blood platelet count (thrombocytopenia). You are more prone to bleeding and bruising.</li><li>Constipation, diarrhoea, nausea, vomiting.</li><li>Pneumonia.</li><li>Chest pain, being short of breath.</li><li>Tiredness (fatigue).</li><li>Injection site reaction including redness, pain or a skin reaction.</li><li>Loss of appetite.</li><li>Joint aches.</li><li>Bruising.</li><li>Rash.</li><li>Red or purple spots under your skin.</li><li>Pain in your belly (abdominal pain).</li><li>Itching.</li><li>Fever.</li><li>Sore nose and throat.</li><li>Dizziness.</li><li>Headache.</li><li>Having trouble sleeping (insomnia).</li><li>Nosebleeds (epistaxis).</li><li>Muscle aches.</li><li>Weakness (asthenia).</li><li>Weight loss.</li><li>Low levels of potassium in your blood.</li></ul><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><ul><li>Bleeding inside your head.</li><li>An infection of the blood caused by bacteria (sepsis). This may be due to low levels of white cells in your blood.</li><li>Bone marrow failure. This can cause low levels of red and white blood cells and platelets.</li><li>A type of anaemia where your red and white blood cells and platelets are reduced.</li><li>An infection in your urine.</li><li>A viral infection causing cold sores (herpes).</li><li>Bleeding gums, bleeding in the stomach or gut, bleeding from around your back passage due to piles (haemorrhoidal haemorrhage), bleeding in your eye, bleeding under your skin, or into your skin (haematoma).</li><li>Blood in your urine.</li><li>Ulcers of your mouth or tongue.</li><li>Changes to your skin at the injection site. These include swelling, a hard lump, bruising, bleeding into your skin (haematoma), rash, itching and changes in the skin colour.</li><li>Redness of your skin.</li><li>Skin infection (cellulitis).</li><li>An infection of the nose and throat, or sore throat.</li><li>Sore or runny nose or sinuses (sinusitis).</li><li>High or low blood pressure (hypertension or hypotension).</li><li>Being short of breath when you move.</li><li>Pain in your throat and voicebox.</li><li>Indigestion.</li><li>Lethargy.</li><li>Feeling generally unwell.</li><li>Anxiety.</li><li>Being confused.</li><li>Hair loss.</li><li>Kidney failure.</li><li>Dehydration.</li><li>White coating covering tongue, inner cheeks, and sometimes on the roof of your mouth, gums and tonsils (oral fungal infection).</li><li>Fainting.</li><li>A fall in blood pressure when standing (orthostatic hypotension) leading to dizziness when moving to a standing or sitting position.</li><li>Sleepiness, drowsiness (somnolence).</li><li>Bleeding due to a catheter line.</li><li>A disease affecting the gut which can result in fever, vomiting and stomach pain (diverticulitis).</li><li>Fluid around the lungs (pleural effusion).</li><li>Shivering (chills).</li><li>Muscle spasms.</li><li>Raised itchy rash on the skin (urticaria).</li><li>Collection of fluid around the heart (pericardial effusion).</li></ul><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><ul><li>Allergic (hypersensitivity) reaction.</li><li>Shaking.</li><li>Liver failure.</li><li>Large plum-coloured, raised painful patches on the skin with fever.</li><li>Painful skin ulceration (pyoderma gangrenosum).</li><li>Inflammation of the lining around the heart (pericarditis).</li></ul><p><strong>Rare side effects (may affect up to 1 in 1,000 people)</strong></p><ul><li>Dry cough.</li><li>Painless swelling in the finger tips (clubbing).</li><li>Tumour lysis syndrome - Metabolic complications that can occur during treatment of cancer and sometimes even without treatment. These complications are caused by the product of dying cancer cells and may include the following: changes to blood chemistry; high potassium, phosphorus, uric acid, and low calcium consequently leading to changes in kidney function, heartbeat, seizures, and sometimes death.</li></ul><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><ul><li>Infection of the deeper layers of skin, which spreads quickly, damaging the skin and tissue, which can be life-threatening (necrotizing fascitis).</li><li>Serious immune reaction (differentiation syndrome) that may cause fever, cough, difficulty breathing, rash, decreased urine, low blood pressure (hypotension), swelling of the arms or legs and rapid weight gain</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30ᵒC.</p><p>Store in the original package.</p><p>Your doctor, pharmacist or nurse are responsible for storing Zytedin. They are also responsible for preparing and disposing of any unused Zytedin correctly.</p><p><strong>For subcutaneous use</strong></p><p><em>When using immediately</em></p><p>Once the suspension has been prepared it should be administered within 1 hour.</p><p><em>When using later on</em></p><p>If the Zytedin suspension is prepared using water for injections that has not been refrigerated, the suspension must be placed in the refrigerator (2-8&deg;C) immediately after it is prepared and kept refrigerated for up to a maximum of 8 hours.</p><p>If the Zytedin suspension is prepared using water for injections that has been stored in the refrigerator (2-8&deg;C), the suspension must be placed in the refrigerator (2-8&deg;C) immediately after it is prepared and kept refrigerated for up to a maximum of 22 hours.</p><p>The suspension should be allowed up to 30 minutes prior to administration to reach room temperature (20-25&deg;C).</p><p>If large particles are present in the suspension it should be discarded.</p><p><strong>For intravenous use </strong></p><p>Zytedin reconstituted and diluted for intravenous administration may be stored at 25&deg;C, but administration must be completed within 1 hour of reconstitution.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is azacitidine. Each vial contains 100 mg azacitidine.</p><p>The other ingredient is mannitol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zytedin 100 mg Powder for Injection is a white to off white lyophilized powder or cake in colourless glass vials sealed with bromobutyl rubber stoppers and flip-off caps. 
After reconstitution, clear colourless solution free from extraneous visible matter. 
Pack size: 1 Vial.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong></p><p>Thymoorgan Pharmazie GmbH</p><p>Schiffgraben 23</p><p>38690 Goslar,</p><p>Germany</p><p>Tel: + (49-5324) 77010</p><p>Fax: + (49- 5324) 770130<br /><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Center (NPC)</p><p>SFDA Call Center: 19999<br />e-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in c
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو زيتيدين</strong></p><p dir="RTL">زيتيدين هو عامل مضاد للسرطان ينتمي إلى مجموعة من الأدوية تسمى &rsquo;مضادات الأيض&lsquo;. يحتوي زيتيدين على المادة الفعالة &rsquo;أزاسيتيدين&lsquo;.</p><p dir="RTL"><strong>ما هي دواعي استخدام زيتيدين</strong></p><p dir="RTL">يُستخدم زيتيدين لدى البالغين غير القادرين على إجراء زراعة الخلايا الجذعية لعلاج:</p><ul dir="rtl"><li>متلازمات خلل التنسج النقوي عالية الخطورة</li><li>الابيضاض الوحيدي النقوي المزمن.</li><li>ابيضاض الدم النقوي الحاد.</li></ul><p dir="RTL">هذه أمراض تؤثر على نخاع العظام ويمكن أن تسبب مشاكل في الإنتاج الطبيعي لخلايا الدم.</p><p dir="RTL"><strong>كيف يعمل زيتيدين</strong></p><p dir="RTL">يعمل زيتيدين عن طريق إيقاف نمو الخلايا السرطانية. يتم دمج الأزاسيتيدين في المادة الوراثية للخلايا (الحمض النووي الريبي والحمض النووي الريبي منزوع الأكسجين). يُعتقد أنه يعمل عن طريق تغيير الطريقة التي تعمل بها الخلية على تشغيل الجينات وإيقافها وأيضاً عن طريق التدخل في إنتاج الحمض النووي الريبي والحمض النووي الريبي منزوع الأكسجين الجديدين. يُعتقد أن هذه الإجراءات تصحح مشاكل نضوج ونمو خلايا الدم الفتية في نخاع العظام التي تسبب اضطرابات خلل التنسج النقوي، وتقتل الخلايا السرطانية في سرطان الدم.</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي إذا كانت لديك أي أسئلة عن طريقة عمل زيتيدين أو سبب وصف هذا الدواء لك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم زيتيدين&nbsp; </strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية من أزاسيتيدين أو أي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</li><li>إذا كنت تعاني من سرطان الكبد في حالة متقدمة.</li><li>إذا كنتِ ترضعين طبيعياً.</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك، الصيدلي أو الممرض قبل استخدام زيتيدين:</p><ul dir="rtl"><li>إذا كنت تعاني من انخفاض في عدد الصفائح الدموية، خلايا الدم الحمراء أو البيضاء.</li><li>إذا كنت تعاني من مرض في الكلى.</li><li>إذا كنت تعاني من مرض في الكبد.</li><li>إذا عانيت سابقاً من مرض في القلب أو نوبة قلبية أو لديك أي تاريخ مرضي لأمراض الرئة.</li></ul><p dir="RTL">يمكن أن يسبب زيتيدين رد فعل مناعي خطير يسمى &rsquo;متلازمة التمايز&lsquo; (انظر القسم 4).</p><p dir="RTL"><em>فحوصات الدم</em></p><p dir="RTL">ستخضع لفحوصات الدم قبل أن تبدأ العلاج بزيتيدين وفي بداية كل فترة علاج (تسمى &rsquo;الدورة&lsquo;). وهذا للتحقق من أن لديك خلايا دم كافية وأن الكبد والكليتين يؤديان وظيفتهما على النحو الصحيح.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُنصح باستخدام زيتيدين مع الأطفال والمراهقين الذين تقل أعمارهم عن 18 عاماً.</p><p dir="RTL"><strong>الأدوية الأخرى وزيتيدين</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تستخدم، استخدمت مؤخراً، أو قد تستخدم أية أدوية أخرى، ذلك لأن زيتيدين قد يؤثر على طريقة عمل بعض الأدوية الأخرى. كما أن بعض الأدوية الأخرى قد تؤثر على طريقة عمل زيتيدين.</p><p dir="RTL"><strong>الحمل، الرضاعة والخصوبة</strong></p><p dir="RTL"><em>الحمل</em></p><p dir="RTL">يجب عدم استخدام زيتيدين أثناء الحمل لأنه قد يكون ضاراً على الجنين.</p><p dir="RTL">إذا كنت امرأة من الممكن أن تصبحي حاملاً، يجب عليك استخدام وسيلة فعالة لمنع الحمل أثناء أخذ زيتيدين ولمدة 6 أشهر بعد التوقف عن العلاج باستخدام زيتيدين.</p><p dir="RTL">أخبري طبيبك على الفور إذا أصبحت حاملاً أثناء العلاج.</p><p dir="RTL">استشيري طبيبك أو الصيدلي قبل أخذ هذا الدواء إذا كنتِ حاملاً أو مرضعاً، تعتقدين بأنك حامل أو تخططين لذلك.</p><p dir="RTL"><em>الرضاعة الطبيعية</em></p><p dir="RTL">يجب ألا ترضعي رضاعة طبيعية أثناء استخدام أزاسيتيدين. من غير المعروف إذا ما كان هذا الدواء يصل إلى حليب الأم.</p><p dir="RTL"><em>الخصوبة</em></p><p dir="RTL">يجب على الرجال عدم إنجاب طفل أثناء تلقي العلاج باستخدام زيتيدين. يجب على الرجال استخدام وسيلة فعَّالة لمنع الحمل خلال أخذ زيتيدين وحتى 3 أشهر بعد التوقف عن العلاج بزيتيدين.</p><p dir="RTL">أخبر طبيبك إذا كنت ترغب في حفظ الحيوانات المنوية قبل بدء هذا العلاج.</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">تجنب القيادة أو استخدام أي أدوات أو آلات إذا كنت تعاني من آثار جانبية مثل التعب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قبل إعطائك زيتيدين، سيعطيك طبيبك دواءً آخر لمنع الغثيان والقيء في بداية كل دورة علاج.</p><ul dir="rtl"><li>الجرعة الموصى بها 75 ملغم لكل م<sup>2</sup> من مساحة سطح الجسم. سيقرر طبيبك جرعتك من هذا الدواء، اعتماداً على حالتك العامة، طولك ووزنك. سيتحقق طبيبك من تقدم حالتك وقد يغير جرعتك إذا لزم الأمر.</li><li>يتم إعطاء زيتيدين كل يوم لمدة أسبوع. سوف تتكرر &quot;دورة العلاج&quot; هذه كل 4 أسابيع. ستتلقى عادةً من 4-6 دورات علاجية.</li></ul><p dir="RTL">سيعطيك الطبيب أو الممرض هذا الدواء عن طريق الحقن تحت الجلد أو عن طريق التسريب (في الوريد). يمكن إعطاؤه تحت الجلد في فخذك، بطنك أو أعلى ذراعك.</p><p dir="RTL">لمعلومات إضافية عن طريقة الاستخدام، انظر قسم &quot;المعلومات التالية مخصصة لاخصائي الرعاية الصحية فقط&quot;.</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، استشر طبيبك، الصيدلي، أو الممرض</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">أخبر طبيبك على الفور إذا شعرت بأي من الآثار الجانبية التالية:</p><ul dir="rtl"><li>نعاس، ارتعاش، يرقان، انتفاخ البطن وسهولة التعرض للكدمات. قد تكون هذه أعراضاً لفشل الكبد ويمكن أن تكون مهددة للحياة.</li><li>تورم في الساقين والقدمين، آلام في الظهر، انخفاض معدل التبول، زيادة العطش، سرعة النبض، الدوخة والغثيان، قيء أو ضعف الشهية والشعور بالارتباك، الأرق أو التعب. قد تكون هذه أعراضاً للفشل الكلوي ويمكن أن تكون مهددة للحياة.</li><li>حمى. قد يكون هذا بسبب عدوى نتيجة لانخفاض مستويات خلايا الدم البيضاء، والتي يمكن أن تكون مهددة للحياة.</li><li>ألم في الصدر أو ضيق في التنفس قد يصاحبه ارتفاع في درجة الحرارة. قد يكون هذا بسبب عدوى في الرئة تسمى &quot;الالتهاب الرئوي&quot;، ويمكن أن تكون مهددة للحياة.</li><li>النزف. مثل وجود دم في البراز نتيجة نزيف في المعدة أو الأمعاء، أو نزيف داخل رأسك. قد تكون هذه أعراض انخفاض مستويات الصفائح الدموية في الدم.</li><li>صعوبة في التنفس، تورم الشفتين، حكة أو طفح جلدي. قد يكون هذا بسبب رد فعل تحسسي (فرط التحسس).</li></ul><p dir="RTL"><strong><em>تشمل الآثار الجانبية الأخرى:</em></strong></p><p dir="RTL"><strong>آثار جانبية شائعة جداً (قد تؤثر على أكثر من شخص واحد من كل 10 أشخاص)</strong></p><ul dir="rtl"><li>انخفاض عدد خلايا الدم الحمراء (فقر الدم). فقد تشعر بالتعب ويظهر عليك الشحوب.</li><li>انخفاض عدد خلايا الدم البيضاء. قد يكون هذا مصحوباً بحمى. أنت أيضاً أكثر عرضة للإصابة بالعدوى.</li><li>انخفاض عدد الصفائح الدموية (قلة الصفيحات). أنت أكثر عرضة للنزيف والكدمات.</li><li>إمساك، إسهال، غثيان، قيء.</li><li>الالتهاب الرئوي.</li><li>ألم في الصدر وضيق في التنفس.</li><li>التعب (الإعياء).</li><li>تفاعلات في موضع الحقن بما في ذلك احمرار، ألم أو تفاعل جلدي.</li><li>فقدان الشهية.</li><li>آلام المفاصل.</li><li>كدمات.</li><li>طفح.</li><li>بقع حمراء أو أرجوانية تحت جلدك.</li><li>ألم في بطنك (ألم باطني).</li><li>الحكة.</li><li>الحمى.</li><li>التهاب الأنف والحلق.</li><li>الدوخة.</li><li>الصداع.</li><li>مشاكل في النوم (أرق)</li><li>نزيف الأنف (الرُعاف)</li><li>آلام العضلات.</li><li>الضعف (الوهن).</li><li>فقدان الوزن.</li><li>انخفاض مستويات البوتاسيوم في الدم</li></ul><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص)</strong></p><ul dir="rtl"><li>نزيف داخل رأسك.</li><li>عدوى في الدم تسببها البكتيريا (تعفن الدم). قد يكون هذا نتيجة لانخفاض مستويات خلايا الدم البيضاء في دمك.</li><li>فشل نخاع العظم. يمكن أن يتسبب هذا في انخفاض مستويات خلايا الدم الحمراء والبيضاء والصفائح الدموية.</li><li>نوع من فقر الدم حيث تنخفض خلايا الدم الحمراء والبيضاء والصفائح الدموية.</li><li>عدوى في البول.</li><li>عدوى فيروسية تسبب تقرحات البرد (الهربس).</li><li>نزيف اللثة، نزيف في المعدة أو الأمعاء، نزيف حول فتحة الشرج بسبب البواسير (نزيف البواسير)، نزيف في عينك، نزيف تحت الجلد، أو في جلدك (ورم دموي).</li><li>دم في بولك.</li><li>قرح في فمك أو اللسان.</li><li>تغييرات في جلدك في موضع الحقن. ومن هذه التغييرات التورم، ورم شديد، تكدم، النزيف تحت جلدك (ورم دموي)، الطفح الجلدي، الحكة والتغيرات في لون جلدك.</li><li>احمرار الجلد.</li><li>الالتهابات الجلدية (التهاب النسيج الخلوي).</li><li>&nbsp;عدوى في الأنف والحلق، أو التهاب الحلق.</li><li>التهاب أو سيلان الأنف أو الجيوب الأنفية (التهاب الجيوب الأنفية).</li><li>ارتفاع أو انخفاض ضغط الدم (فرط ضغط الدم أو انخفاض ضغط الدم).</li><li>الشعور بضيق في التنفس عند التحرك.</li><li>ألم في الحلق والحنجرة.</li><li>عسر الهضم.</li><li>الخمول.</li><li>الشعور بتوعك بشكل عام.</li><li>القلق.</li><li>الشعور بالارتباك.</li><li>تساقط الشعر.</li><li>الفشل الكلوي.</li><li>الجفاف.</li><li>طبقة بيضاء تغطي اللسان، الخدود من الداخل وأحياناً على سقف الفم، اللثة واللوزتين (فطريات فموية).</li><li>الإغماء.</li><li>انخفاض ضغط الدم عند الوقوف (انخفاض ضغط الدم الانتصابي) يؤدي إلى دوخة عند التغيير إلى وضعية الوقوف أو الجلوس.</li><li>النعاس، الدوخة (النيمومة).</li><li>نزيف بسبب خط القسطرة.</li><li>مرض يصيب الأمعاء ويمكن أن يؤدي إلى الحمى، القيء وآلام في المعدة (التهاب القناة الغذائية).</li><li>سوائل حول الرئتين (الانصباب الجنبي).</li><li>الارتعاش (القشعريرة).</li><li>التشنجات العضلية.</li><li>طفح جلدي مثير للحكة على الجلد (شرى).</li><li>تجمع سوائل حول القلب (الانصباب التأموري).</li></ul><p><strong>آثار جانبية غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص)</strong></p><ul dir="rtl"><li>تفاعلات تحسسية (فرط التحسس).</li><li>الارتعاش.</li><li>فشل كبدي.</li><li>بقع كبيرة مؤلمة بارزة وردية على الجلد مصحوبة بالحمى.</li><li>تقرح الجلد المؤلم (تقيح الجلد الغنغريني).</li><li>التهاب الغشاء المبطن للقلب (التهاب التأمور).</li></ul><p dir="RTL"><strong>آثار جانبية نادرة (قد تؤثر على ما يصل إلى شخص واحد من كل 1000&nbsp;شخص)</strong></p><ul dir="rtl"><li>السعال الجاف.</li><li>تورم غير مؤلم في أطراف الأصابع (التعجر).</li><li>متلازمة تحلل الورم - المضاعفات الأيضية التي يمكن أن تحدث أثناء علاج السرطان وحتى بدون العلاج أحياناً. تحدث هذه المضاعفات بسبب منتجات الخلايا السرطانية الميتة وقد تتضمن التالي: حدوث تغيرات في كيمياء الدم؛ ارتفاع البوتاسيوم، الفوسفور، حمض اليوريك، وانخفاض الكالسيوم مما يؤدي إلى حدوث تغيرات في وظائف الكلى، معدل نبضات القلب، التشنجات، والوفاة أحياناً.</li></ul><p dir="RTL"><strong>آثار جانبية غير معروفة (لا يمكن تقدير تكرارها من البيانات المتاحة)</strong></p><ul dir="rtl"><li>عدوى في الطبقات العميقة من الجلد، والتي تنتشر بسرعة، مسببة ضرراً في الجلد والأنسجة، والذي قد يكون مهدداً للحياة (التهاب اللفافة النخري).</li><li>رد فعل مناعي خطير (متلازمة التمايز) الذي قد يسبب الحمى، السعال، صعوبة التنفس، الطفح الجلدي، نقص البول، ضغط دم منخفض (انخفاض ضغط الدم)، تورم في الذراعين أو الساقين وزيادة الوزن بسرعة</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">طبيبك، الصيدلي أو الممرض هو المسؤول عن تخزين زيتيدين. كما أنهم مسؤولون عن تحضير أي زيتيدين غير مستخدم والتخلص منه على النحو الصحيح.</p><p dir="RTL"><strong>للاستخدام تحت الجلد</strong></p><p dir="RTL"><em>عند الاستخدام على الفور</em></p><p dir="RTL">بمجرد تحضير المعلق يجب إعطائه خلال ساعة واحدة.</p><p dir="RTL"><em>عند الاستخدام لاحقاً</em></p><p dir="RTL">إذا تم تحضير معلق زيتيدين باستخدام ماء معد للحقن غير مبرد، فيجب وضع المعلق في الثلاجة (2-8&deg; مئوية) على الفور بعد تحضيره ويحفظ مبرد لحد أقصى 8 ساعات.</p><p dir="RTL">إذا تم تحضير معلق زيتيدين باستخدام ماء معد للحقن الذي تم حفظه داخل الثلاجة (2-8&deg; مئوية)، فيجب وضع المعلق في الثلاجة (2-8&deg; مئوية) على الفور بعد تحضيره ويحفظ مبرد لحد أقصى 22 ساعة.</p><p dir="RTL">يجب ترك المعلق لمدة 30 دقيقة قبل الإعطاء للوصول إلى درجة حرارة الغرفة (20-25&deg; مئوية).</p><p dir="RTL">يجب التخلص من المعلق في حالة وجود جزيئات كبيرة فيه.</p><p dir="RTL"><strong>للاستخدام الوريدي </strong></p><p dir="RTL">يمكن حفظ زيتيدين المحضر والمخفف للإعطاء عن طريق الوريد عند درجة حرارة 25&deg; مئوية، ولكن يجب إكمال الإعطاء خلال ساعة واحدة من التحضير.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي أزاسيتيدين.</p><p dir="RTL">تحتوي كل زجاجة من زيتيدين 100 ملغم مسحوق للحقن على 100 ملغم أزاسيتيدين.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي المانيتول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">زيتيدين 100 ملغم مسحوق للحقن هو مسحوق أبيض مائل إلى الأبيض المصفر مجفف بالتجميد أو كتلة في زجاجات عديمة اللون محكمة الإغلاق بسدادات مطاطية من البروموبوتيل وأغطية قابلة للفتح لأعلى.</p><p dir="RTL">بعد التحضير: محلول صافٍ عديم اللون خالٍ من المواد المرئية الدخيلة.</p><p dir="RTL">حجم العبوة: زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنّعة</strong></p><p dir="RTL">شركة أدوية ثايمورغان ذات المسؤولية المحدودة</p><p dir="RTL">شارع شيفجرابين 23،</p><p dir="RTL">38690 غوسلار،</p><p dir="RTL">ألمانيا</p><p dir="RTL">هاتف: 77010 (5324-49) +</p><p dir="RTL">فاكس: 770130 (5324-49) +</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp; </strong>المملكة العربية السعودية</p><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; دول الخليج العربي الأخرى</p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 07/2023؛ رقم النسخة: SA2.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zytedin 100 mg Powder for Injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 100 mg azacitidine.

For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for injection.
White to off white lyophilized powder or cake. 
After reconstitution, clear colourless solution free from extraneous visible matter. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zytedin is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:</p><ul><li>Intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),</li><li>Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder,</li><li>Acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,</li><li>AML with &gt;30% marrow blasts according to the WHO classification.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zytedin treatment should be initiated and monitored under the supervision of a physician experienced in the use of chemotherapeutic agents. Patients should be premedicated with anti-emetics for nausea and vomiting.</p><p><strong><em>Posology</em></strong></p><p>The recommended starting dose for the first treatment cycle, for all patients regardless of baseline haematology laboratory values, is 75 mg/m<sup>2</sup> of body surface area, injected subcutaneously or intravenously, daily for 7 days.</p><p>It is recommended that patients be treated for a minimum of 4-6 cycles. Treatment should be continued as long as the patient continues to benefit or until disease progression.</p><p>Patients should be monitored for haematologic response/toxicity and renal toxicities (see section 4.4); a delay in starting the next cycle or a dose reduction as described below may be necessary.</p><p><strong>Dosage</strong></p><p><em>Dosage Adjustment Based on Hematology Laboratory Values</em></p><ul><li>For adult patients with baseline (start of treatment) WBC greater than or equal to 3.0 x10<sup>9</sup>/L, ANC greater than or equal to 1.5 x10<sup>9</sup>/L, and platelets greater than or equal to 75.0 x10<sup>9</sup>/L, adjust the dose as follows, based on nadir counts for any given cycle:</li></ul><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Nadir Counts</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>% Dose in the Next Course</strong></p></td></tr><tr><td style="vertical-align:top"><p>ANC (x10<sup>9</sup>/L)</p></td><td style="vertical-align:top"><p>Platelets (x10<sup>9</sup>/L)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Less than 0.5</p></td><td style="vertical-align:top"><p>Less than 25</p></td><td style="vertical-align:top"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>0.5 - 1.5</p></td><td style="vertical-align:top"><p>25 - 50</p></td><td style="vertical-align:top"><p>67%</p></td></tr><tr><td style="vertical-align:top"><p>Greater than 1.5</p></td><td style="vertical-align:top"><p>Greater than 50</p></td><td style="vertical-align:top"><p>100%</p></td></tr></tbody></table><ul><li>For adult patients whose baseline counts are WBC less than 3.0 x10<sup>9</sup>/L, ANC less than 1.5 x10<sup>9</sup>/L, or platelets less than 75.0 x10<sup>9</sup>/L, base dose adjustments on nadir counts and bone marrow biopsy cellularity at the time of the nadir as noted below, unless there is clear improvement in differentiation (percentage of mature granulocytes is higher and ANC is higher than at onset of that course) at the time of the next cycle, in which case continue the current dose.</li></ul><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top; width:334px"><p><strong>WBC or Platelet Nadir % decrease in counts from baseline</strong></p></td><td colspan="4" style="vertical-align:top; width:696px"><p><strong>Bone Marrow</strong></p><p><strong>Biopsy Cellularity at Time of Nadir (%)</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top; width:394px"><p>30-60</p></td><td style="vertical-align:top"><p>15-30</p></td><td style="vertical-align:top"><p>Less than 15z</p></td></tr><tr><td style="vertical-align:top; width:334px"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top; width:696px"><p><strong>% Dose in the next course</strong></p></td></tr><tr><td style="vertical-align:top; width:334px"><p>50 - 75</p></td><td style="vertical-align:top; width:395px"><p>100</p></td><td colspan="2" style="vertical-align:top; width:106px"><p>50</p></td><td style="vertical-align:top"><p>33</p></td></tr><tr><td style="vertical-align:top; width:334px"><p>Greater than 75</p></td><td style="vertical-align:top; width:395px"><p>75</p></td><td colspan="2" style="vertical-align:top; width:106px"><p>50</p></td><td style="vertical-align:top"><p>33</p></td></tr></tbody></table><p>If a nadir as defined in the table above has occurred, give the next course 28 days after the start of the preceding course, provided that both the WBC and the platelet counts are greater than 25% above the nadir and rising. If a greater than 25% increase above the nadir is not seen by day 28, reassess counts every 7 days. If a 25% increase is not seen by day 42, reduce the scheduled dose by 50%.</p><p><em>Dosage Adjustment Based on Serum Electrolytes and Renal Toxicity </em></p><p>If unexplained reductions in serum bicarbonate levels to less than 20 mEq/L occur, reduce the dosage by 50% for the next course. Similarly, if unexplained elevations of BUN or serum creatinine occur, delay the next cycle until values return to normal or baseline and reduce the dose by 50% for the next course.&nbsp;</p><p><em>Use in Geriatric Patients</em></p><p>Azacitidine and its metabolites are known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, select the dose carefully and monitor renal function.</p><p><strong><em>Method of administration</em></strong></p><p><strong>For subcutaneous use</strong></p><p>Reconstituted Zytedin should be injected subcutaneously into the upper arm, thigh or abdomen. Injection sites should be rotated. New injections should be given at least 2.5 cm from the previous site and never into areas where the site is tender, bruised, red, or hardened.</p><p>After reconstitution, the suspension should not be filtered. For instructions on reconstitution of the medicinal product before administration, see section 6.6. &nbsp;</p><p><strong>For intravenous use&nbsp; </strong></p><p>Zytedin solution is administered intravenously. Administer the total dose over a period of 10-40 minutes. The administration must be completed within 1 hour of reconstitution of the Zytedin vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Advanced malignant hepatic tumours (see section 4.4).
•	Breast-feeding (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Haematological toxicity</strong></p><p>Treatment with azacitidine is associated with anaemia, neutropenia and thrombocytopenia, particularly during the first 2 cycles (see section 4.8). Complete blood counts should be performed as needed to monitor response and toxicity, but at least prior to each treatment cycle. After administration of the recommended dose for the first cycle, the dose for subsequent cycles should be reduced or its administration delayed based on nadir counts and haematological response (see section 4.2). Patients should be advised to promptly report febrile episodes. Patients and physicians are also advised to be observant for signs and symptoms of bleeding.</p><p><strong>Hepatic impairment</strong></p><p>No formal studies have been conducted in patients with hepatic impairment. Patients with extensive tumour burden due to metastatic disease have been reported to experience progressive hepatic coma and death during azacitidine treatment, especially in such patients with baseline serum albumin &lt; 30 g/L. Azacitidine is contraindicated in patients with advanced malignant hepatic tumours (see section 4.3).</p><p><strong>Renal impairment</strong></p><p>Renal abnormalities ranging from elevated serum creatinine to renal failure and death were reported in patients treated with intravenous azacitidine in combination with other chemotherapeutic agents. In addition, renal tubular acidosis, defined as a fall in serum bicarbonate to &lt; 20 mmol/L in association with an alkaline urine and hypokalaemia (serum potassium &lt; 3 mmol/L) developed in 5 subjects with chronic myelogenous leukaemia (CML) treated with azacitidine and etoposide. If unexplained reductions in serum bicarbonate (&lt; 20 mmol/L) or elevations of serum creatinine or BUN occur, the dose should be reduced or administration delayed (see section 4.2).</p><p>Patients should be advised to report oliguria and anuria to the health care provider immediately.</p><p>Although no clinically relevant differences in the frequency of adverse reactions were noted between subjects with normal renal function compared to those with renal impairment, patients with renal impairment should be closely monitored for toxicity since azacitidine and/or its metabolites are primarily excreted by the kidney (see section 4.2).</p><p><strong>Laboratory tests</strong></p><p>Liver function tests, serum creatinine and serum bicarbonate should be determined prior to initiation of therapy and prior to each treatment cycle. Complete blood counts should be performed prior to initiation of therapy and as needed to monitor response and toxicity, but at a minimum, prior to each treatment cycle, see also section 4.8.</p><p><strong>Cardiac and pulmonary disease</strong></p><p>Patients with a history of severe congestive heart failure, clinically unstable cardiac disease or pulmonary disease were excluded from the pivotal registration studies (AZA PH GL 2003 CL 001 and AZA-AML-001) and therefore the safety and efficacy of azacitidine in these patients has not been established. Recent data from a clinical trial in patients with a known history of cardiovascular or pulmonary disease showed a significantly increased incidence of cardiac events with azacitidine (see section 4.8). It is therefore advised to exercise caution when prescribing azacitidine to these patients. Cardiopulmonary assessment before and during the treatment should be considered.</p><p><strong>Necrotising fasciitis </strong></p><p>Necrotising fasciitis, including fatal cases, have been reported in patients treated with azacitidine. Azacitidine therapy should be discontinued in patients who develop necrotising fasciitis and appropriate treatment should be promptly initiated.</p><p><strong>Tumour lysis syndrome</strong></p><p>The patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on <em>in vitro</em> data, azacitidine metabolism does not appear to be mediated by cytochrome P450 isoenzymes (CYPs), UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), and glutathione transferases (GSTs); interactions related to these metabolizing enzymes <em>in vivo</em> are therefore considered unlikely.</p><p>Clinically significant inhibitory or inductive effects of azacitidine on cytochrome P450 enzymes are unlikely (see section 5.2).</p><p>No formal clinical drug interaction studies with azacitidine have been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Women of childbearing potential/Contraception in males and females</strong></p><p>Women of childbearing potential and men have to use effective contraception during and up to 3 months after treatment.</p><p><strong>Pregnancy</strong></p><p>There are no adequate data on the use of azacitidine in pregnant women. Studies in mice have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Based on results from animal studies and its mechanism of action, azacitidine should not be used during pregnancy, especially during the first trimester, unless clearly necessary. The advantages of treatment should be weighed against the possible risk for the foetus in every individual case.</p><p><strong>Breast-feeding</strong></p><p>It is not known whether azacitidine/metabolites are excreted in human milk. Due to the potential serious adverse reactions in the nursing child, breast-feeding is contraindicated during azacitidine therapy.</p><p><strong>Fertility</strong></p><p>There are no human data on the effect of azacitidine on fertility. In animals, adverse reactions with azacitidine use on male fertility have been documented (see section 5.3). Men should be advised not to father a child while receiving treatment and must use effective contraception during and up to 3 months after treatment. Before starting treatment, male patients should be advised to seek counselling on sperm storage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azacitidine has minor or moderate influence on the ability to drive and use machines. Fatigue has been reported with the use of azacitidine. Therefore, caution is recommended when driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p><em>Adult population with MDS, CMML and AML (20-30% marrow blasts)</em></p><p>Adverse reactions considered to be possibly or probably related to the administration of azacitidine have occurred in 97% of patients.</p><p>The most common serious adverse reactions noted from the pivotal study (AZA PH GL 2003 CL 001) included febrile neutropenia (8.0%) and anaemia (2.3%), which were also reported in the supporting studies (CALGB 9221 and CALGB 8921). Other serious adverse reactions from these 3 studies included infections such as neutropenic sepsis (0.8%) and pneumonia (2.5%) (some with fatal outcome), thrombocytopenia (3.5%), hypersensitivity reactions (0.25%) and haemorrhagic events (e.g. cerebral haemorrhage [0.5%], gastrointestinal haemorrhage [0.8%] and intracranial haemorrhage [0.5%])).</p><p>The most commonly reported adverse reactions with azacitidine treatment were haematological reactions (71.4%) including thrombocytopenia, neutropenia and leukopenia (usually Grade 3-4), gastrointestinal events (60.6%) including nausea, vomiting (usually Grade 1-2) or injection site reactions (77.1%; usually Grade 1-2).</p><p><em>Adult population aged 65 years or older with AML with &gt; 30% marrow blasts </em></p><p>The most common serious adverse reactions (&ge; 10%) noted from AZA-AML-001 within the azacitidine treatment arm included febrile neutropenia (25.0%), pneumonia (20.3%), and pyrexia (10.6%). Other less frequently reported serious adverse reactions in the azacitidine treatment arm included sepsis (5.1%), anaemia (4.2%), neutropenic sepsis (3.0%), urinary tract infection (3.0%), thrombocytopenia (2.5%), neutropenia (2.1%), cellulitis (2.1%), dizziness (2.1%) and dyspnoea (2.1%).</p><p>The most commonly reported (&ge; 30%) adverse reactions with azacitidine treatment were gastrointestinal events, including constipation (41.9%), nausea (39.8%), and diarrhoea (36.9%), (usually Grade 1-2), general disorders and administration site conditions including pyrexia (37.7%; usually Grade 1-2) and haematological events, including febrile neutropenia (32.2%) and neutropenia (30.1%), (usually Grade 3-4).</p><p><strong>Tabulated list of adverse reactions </strong></p><p>Table 1 below contains adverse reactions associated with azacitidine treatment obtained from the main clinical studies in MDS and AML and post marketing surveillance.</p><p>Frequencies are defined as: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Adverse reactions are presented in the table below according to the highest frequency observed in any of the main clinical studies.</p><p><strong>Table 1: ADRs reported in patients with MDS or AML treated with azacitidine (clinical studies and post- marketing)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not Known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>pneumonia* (including bacterial, viral and fungal), nasopharyngitis</p></td><td style="vertical-align:top"><p>sepsis* (including bacterial, viral and fungal), neutropenic sepsis*, respiratory tract infection (includes upper and bronchitis), urinary tract infection, cellulitis, diverticulitis, oral fungal infection, sinusitis, pharyngitis, rhinitis, herpes simplex, skin infection</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>necrotising fasciitis *</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>febrile neutropenia*, neutropenia, leukopenia, thrombocytopenia, anaemia</p></td><td style="vertical-align:top"><p>pancytopenia*, bone marrow failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypersensitivity reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>anorexia, decreased appetite, hypokalemia</p></td><td style="vertical-align:top"><p>dehydration</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>tumour lysis syndrome</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>insomnia</p></td><td style="vertical-align:top"><p>confusional state, anxiety</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>dizziness, headache</p></td><td style="vertical-align:top"><p>intracranial haemorrhage*, syncope, somnolence, lethargy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eye haemorrhage, conjunctival haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>pericardial effusion</p></td><td style="vertical-align:top"><p>pericarditis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypotension*, hypertension, orthostatic hypotension, haematoma</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>dyspnoea, epistaxis</p></td><td style="vertical-align:top"><p>pleural effusion, dyspnoea exertional, pharyngolaryngeal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>interstitial lung disease</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>diarrhoea, vomiting, constipation, nausea, abdominal pain (includes upper and abdominal discomfort)</p></td><td style="vertical-align:top"><p>gastrointestinal haemorrhage* (includes mouth haemorrhage), haemorrhoidal haemorrhage, stomatitis, gingival bleeding, dyspepsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hepatic failure*, progressive hepatic coma</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>petechiae, pruritus (includes generalized), rash, ecchymosis</p></td><td style="vertical-align:top"><p>purpura, alopecia, urticaria, erythema, rash macular</p></td><td style="vertical-align:top"><p>acute febrile neutrophilic dermatosis, pyoderma gangrenosum</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal, and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>arthralgia, musculoskeletal pain (includes back, bone and pain in extremity)</p></td><td style="vertical-align:top"><p>muscle spasms, myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>renal failure*, haematuria, elevated serum creatinine</p></td><td style="vertical-align:top"><p>renal tubular acidosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>pyrexia*, fatigue, asthenia, chest pain, injection site erythema, injection site pain, injection site reaction (unspecified)</p></td><td style="vertical-align:top"><p>bruising, haematoma, induration, rash, pruritus, inflammation, discoloration, nodule and haemorrhage (at injection site), malaise, chills, catheter site hemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>injection site necrosis (at injection site)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>weight decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* = rarely fatal cases have been reported</p><p><strong>Description of selected adverse reactions</strong></p><p><em>Haematologic adverse reactions</em></p><p>The most commonly reported (&ge; 10%) haematological adverse reactions associated with azacitidine treatment include anaemia, thrombocytopenia, neutropenia, febrile neutropenia and leukopenia, and were usually Grade 3 or 4. There is a greater risk of these events occurring during the first 2 cycles, after which they occur with less frequency in patients with restoration of haematological function. Most haematological adverse reactions were managed by routine monitoring of complete blood counts and delaying azacitidine administration in the next cycle, prophylactic antibiotics and/or growth factor support (e.g. G-CSF) for neutropenia and transfusions for anaemia or thrombocytopenia as required.</p><p><em>Infections</em></p><p>Myelosuppression may lead to neutropenia and an increased risk of infection. Serious adverse reactions such as sepsis, including neutropenic sepsis, and pneumonia were reported in patients receiving azacitidine, some with a fatal outcome. Infections may be managed with the use of anti-infectives plus growth factor support (e.g. G-CSF) for neutropenia.</p><p><em>Bleeding </em></p><p>Bleeding may occur with patients receiving azacitidine. Serious adverse reactions such as gastrointestinal haemorrhage and intracranial haemorrhage have been reported. Patients should be monitored for signs and symptoms of bleeding, particularly those with pre-existing or treatment-related thrombocytopenia.</p><p><em>Hypersensitivity</em></p><p>Serious hypersensitivity reactions have been reported in patients receiving azacitidine. In case of an anaphylactic-like reaction, treatment with azacitidine should be immediately discontinued and appropriate symptomatic treatment initiated.</p><p><em>Skin and subcutaneous tissue adverse reactions</em></p><p>The majority of skin and subcutaneous adverse reactions were associated with the injection site. None of these adverse reactions led to discontinuation of azacitidine, or reduction of azacitidine dose in the pivotal studies. The majority of adverse reactions occurred during the first 2 cycles and tended to decrease with subsequent cycles. Subcutaneous adverse reactions such as injection site rash/inflammation/pruritus, rash, erythema and skin lesion may require management with concomitant medicinal products, such as antihistamines, corticosteroids and non-steroidal anti-inflammatory medicinal products (NSAIDs). These cutaneous reactions have to be distinguished from soft tissue infections, sometimes occurring at injection site. Soft tissue infections, including cellulitis and necrotising fasciitis in rare cases leading to death, have been reported with azacitidine in the post marketing setting. For clinical management of infectious adverse reactions, see section 4.8 Infections.</p><p><em>Gastrointestinal adverse reactions</em></p><p>The most commonly reported gastrointestinal adverse reactions associated with azacitidine treatment included constipation, diarrhoea, nausea and vomiting. These adverse reactions were managed symptomatically with anti-emetics for nausea and vomiting; anti-diarrhoeals for diarrhoea, and laxatives and/or stool softeners for constipation.</p><p><em>Renal adverse reactions</em></p><p>Renal abnormalities, ranging from elevated serum creatinine and haematuria to renal tubular acidosis, renal failure and death were reported in patients treated with azacitidine (see section 4.4).</p><p><em>Hepatic adverse reactions</em></p><p>Patients with extensive tumour burden due to metastatic disease have been reported to experience hepatic failure, progressive hepatic coma and death during azacitidine treatment (see section 4.4).</p><p><em>Cardiac events</em></p><p>Data from a clinical trial allowing enrolment of patients with known history of cardiovascular or pulmonary disease showed a statistically significant increase in cardiac events in patients with newly diagnosed AML treated with azacitidine (see section 4.4).</p><p><em>Elderly population </em></p><p>There is limited safety information available with azacitidine in patients &ge;85 years (with 14 [5.9%] patients &ge;85 years in AZA-AML-001 study).</p><p><strong>Reporting of suspected adverse events</strong><u>&nbsp; </u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Center (NPC)</p><p>SFDA Call Center: 19999<br />e-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>One case of overdose with azacitidine was reported during clinical trials. A patient experienced diarrhoea, nausea, and vomiting after receiving a single intravenous dose of approximately 290 mg/m<sup>2</sup>, almost 4 times the recommended starting dose.</p><p>In the event of overdose, the patient should be monitored with appropriate blood counts and should receive supportive treatment, as necessary. There is no known specific antidote for azacitidine overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, pyrimidine analogues; ATC code: L01BC07</p><p><strong>Mechanism of action</strong></p><p>Azacitidine is believed to exert its antineoplastic effects by multiple mechanisms including cytotoxicity on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA. The cytotoxic effects of azacitidine may result from multiple mechanisms, including inhibition of DNA, RNA and protein synthesis, incorporation into RNA and DNA, and activation of DNA damage pathways. Non-proliferating cells are relatively insensitive to azacitidine. Incorporation of azacitidine into DNA results in the inactivation of DNA methyltransferases, leading to hypomethylation of DNA. DNA hypomethylation of aberrantly methylated genes involved in normal cell cycle regulation, differentiation and death pathways may result in gene re-expression and restoration of cancer-suppressing functions to cancer cells. The relative importance of DNA hypomethylation versus cytotoxicity or other activities of azacitidine to clinical outcomes has not been established.</p><p><strong>Clinical efficacy and safety</strong></p><p><em>Adult population (MDS, CMML and AML [20-30% marrow blasts])</em></p><p>The efficacy and safety of azacitidine were studied in an international, multicenter, controlled, open-label, randomised, parallel-group, Phase 3 comparative study (AZA PH GL 2003 CL 001) in adult patients with: intermediate-2 and high-risk MDS according to the International Prognostic Scoring System (IPSS), refractory anaemia with excess blasts (RAEB), refractory anaemia with excess blasts in transformation (RAEB-T) and modified chronic myelomonocytic leukaemia (mCMML) according to the French American British (FAB) classification system. RAEB-T patients (21-30% blasts) are now considered to be AML patients under the current WHO classification system. Azacitidine plus best supportive care (BSC) (n = 179) was compared to conventional care regimens (CCR). CCR consisted of BSC alone (n = 105), low-dose cytarabine plus BSC (n = 49) or standard induction chemotherapy plus BSC (n = 25). Patients were pre-selected by their physician to 1 of the 3 CCR prior to randomisation. Patients received this pre-selected regimen if not randomised to azacitidine. As part of the inclusion criteria, patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients with secondary MDS were excluded from the study. The primary endpoint of the study was overall survival. Azacitidine was administered at a subcutaneous dose of 75 mg/m<sup>2</sup> daily for 7 days, followed by a rest period of 21 days (28-day treatment cycle) for a median of 9 cycles (range = 1-39) and a mean of 10.2 cycles. Within the Intent to Treat population (ITT), the median age was 69 years (range 38 to 88 years).</p><p>In the ITT analysis of 358 patients (179 azacitidine and 179 CCR), azacitidine treatment was associated with a median survival of 24.46 months versus 15.02 months for those receiving CCR treatment, a difference of 9.4 months, with a stratified log-rank p-value of 0.0001. The hazard ratio for the treatment effect was 0.58 (95% CI: 0.43, 0.77). The two-year survival rates were 50.8% in patients receiving azacitidine <em>versus</em> 26.2% in patients receiving CCR (p &lt; 0.0001).</p><p><img src="data:image/png;base64,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" alt="" width="587" height="398" vspace="0" hspace="0" border="0" style="width:587px;height:398px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>KEY: AZA = azacitidine; CCR = conventional care regimens; CI = confidence interval; HR = hazard ratio</p><p>The survival benefits of azacitidine were consistent regardless of the CCR treatment option (BSC alone, low-dose cytarabine plus BSC or standard induction chemotherapy plus BSC) utilised in the control arm.</p><p>When IPSS cytogenetic subgroups were analysed, similar findings in terms of median overall survival were observed in all groups (good, intermediate, poor cytogenetics, including monosomy 7).</p><p>On analyses of age subgroups, an increase in median overall survival was observed for all groups (&lt; 65 years, &ge; 65 years and &ge; 75 years).</p><p>Azacitidine treatment was associated with a median time to death or transformation to AML of 13.0 months versus 7.6 months for those receiving CCR treatment, an improvement of 5.4 months with a stratified log-rank p-value of 0.0025.</p><p>Azacitidine treatment was also associated with a reduction in cytopenias, and their related symptoms. Azacitidine treatment led to a reduced need for red blood cell (RBC) and platelet transfusions. Of the patients in the azacitidine group who were RBC transfusion dependent at baseline, 45.0% of these patients became RBC transfusion independent during the treatment period, compared with 11.4% of the patients in the combined CCR groups (a statistically significant (p &lt; 0.0001) difference of 33.6% (95% CI: 22.4, 44.6). In patients who were RBC transfusion dependent at baseline and became independent, the median duration of RBC transfusion independence was 13 months in the azacitidine group.</p><p>Response was assessed by the investigator or by the Independent Review Committee (IRC). Overall response (complete remission [CR] + partial remission [PR]) as determined by the investigator was 29% in the azacitidine group and 12% in the combined CCR group (p = 0.0001). Overall response (CR + PR) as determined by the IRC in AZA PH GL 2003 CL 001 was 7% (12/179) in the azacitidine group compared with 1% (2/179) in the combined CCR group (p = 0.0113). The differences between the IRC and investigator assessments of response were a consequence of the International Working Group (IWG) criteria requiring improvement in peripheral blood counts and maintenance of these improvements for a minimum of 56 days. A survival benefit was also demonstrated in patients that had not achieved a complete/partial response following azacitidine treatment. Haematological improvement (major or minor) as determined by the IRC was achieved in 49% of patients receiving azacitidine compared with 29% of patients treated with combined CCR (p &lt; 0.0001).</p><p>In patients with one or more cytogenetic abnormalities at baseline, the percentage of patients with a major cytogenetic response was similar in the azacitidine and combined CCR groups. Minor cytogenetic response was statistically significantly (p = 0.0015) higher in the azacitidine group (34%) compared with the combined CCR group (10%).</p><p><em>Adult population aged 65 years or older with AML with &gt; 30% marrow blasts </em></p><p>The results presented below represent the intent-to-treat population studied in AZA-AML-001 (see section 4.1 for the approved indication).</p><p>The efficacy and safety of azacitidine was studied in an international, multicentre, controlled, open-label, parallel group Phase 3 study in patients 65 years and older with newly diagnosed de novo or secondary AML with &gt;30% bone marrow blasts according to the WHO classification, who were not eligible for HSCT. Azacitidine plus BSC (n=241) was compared to CCR. CCR consisted of BSC alone (n=45), low-dose cytarabine plus BSC (n=158), or standard intensive chemotherapy with cytarabine and anthracycline plus BSC (n=44). Patients were pre-selected by their physician to 1 of the 3 CCRs prior to randomization. Patients received the pre-selected regimen if not randomised to azacitidine. As part of the inclusion criteria, patients were required to have an ECOG performance status of 0-2 and intermediate- or poor-risk cytogenetic abnormalities. The primary endpoint of the study was overall survival.</p><p>Azacitidine was administered at a SC dose of 75mg/m<sup>2</sup>/day for 7 days, followed by a rest period of 21 days (28 day treatment cycle), for a median of 6 cycles (range: 1 to 28), BSC- only patients for a median of 3 cycles (range: 1 to 20), low-dose cytarabine patients for a median of 4 cycles (range 1 to 25) and standard intensive chemotherapy patients for a median of 2 cycles (range: 1 to 3, induction cycle plus 1 or 2 consolidation cycles).</p><p>The individual baseline parameters were comparable between the azacitidine and CCR groups. The median age of the subjects was 75.0 years (range: 64 to 91 years), 75.2% were Caucasian and 59.0% were male. At baseline 60.7% were classified as AML not otherwise specified, 32.4% AML with myelodysplasia-related changes, 4.1% therapy-related myeloid neoplasms and 2.9% AML with recurrent genetic abnormalities according to the WHO classification.</p><p>In the ITT analysis of 488 patients (241 azacitidine and 247 CCR), azacitidine treatment was associated with a median survival of 10.4 months versus 6.5 months for those receiving CCR treatment, a difference of 3.8 months, with a stratified log-rank p-value of 0.1009 (two- sided). The hazard ratio for the treatment effect was 0.85 (95% CI= 0.69, 1.03). The one-year survival rates were 46.5% in patients receiving azacitidine versus 34.3% in patients receiving CCR.</p><p><img src="data:image/png;base64,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" alt="" width="570" height="361" vspace="0" hspace="0" border="0" style="width:570px;height:361px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>The Cox PH model adjusted for pre-specified baseline prognostic factors defined a HR for azacitidine versus CCR of 0.80 (95% CI= 0.66, 0.99; p = 0.0355).</p><p>In addition, although the study was not powered to demonstrate a statistically significant difference when comparing azacitidine to the preselection CCR treatment groups, the survival of azacitidine treated patients was longer when compared to CCR treatment options BSC alone, low-dose cytarabine plus BSC and were similar when compared to standard intensive chemotherapy plus BSC.</p><p>In all pre- specified subgroups age [(&lt; 75 years &amp; &ge; 75 years), gender, race, ECOG performance status (0 or 1 &amp; 2), baseline cytogenetic risk (intermediate &amp; poor), geographic region, WHO classification of AML (including AML with myelodysplasia-related changes), baseline WBC count (&le; 5 x10<sup>9</sup>/L &amp; &gt;5 x 10<sup>9</sup>/L), baseline bone marrow blasts ( &le; 50% &amp; &gt; 50%) and prior history of MDS] there was a trend in OS benefit in favour of azacitidine. In a few pre-specified subgroups, the OS HR reached statistical significance including patients with poor cytogenetic risk, patients with AML with myelodysplasia-related changes, patients &lt; 75 years, female patients and white patients.</p><p>Haematologic and cytogenetic responses were assessed by the investigator and by the IRC with similar results. Overall response rate (complete remission [CR] + complete remission with incomplete blood count recovery [CRi]) as determined by the IRC was 27.8% in the azacitidine group and 25.1% in the combined CCR group (p = 0.5384). In patients who achieved CR or CRi, the median duration of remission was 10.4 months (95% CI = 7.2, 15.2) for the azacitidine subjects and 12.3 months (95% CI = 9.0, 17.0) for the CCR subjects. A survival benefit was also demonstrated in patients that had not achieved a complete response for azacitidine compared to CCR.</p><p>Azacitidine treatment improved peripheral blood counts and led to a reduced need for RBC and platelet transfusions. A patient was considered RBC or platelet transfusion dependent at baseline if the subject had one or more RBC or platelet transfusions during the 56 days (8 weeks) on or prior to randomization, respectively. A patient was considered RBC or platelet transfusion independent during the treatment period if the subject had no RBC or platelet transfusions during any consecutive 56 days during the reporting period, respectively.</p><p>Of the patients in the azacitidine group who were RBC transfusion dependent at baseline, 38.5% (95% CI = 31.1, 46.2) of these patients became RBC transfusion independent during the treatment period, compared with 27.6% of (95% CI = 20.9, 35.1) patients in the combined CCR groups. In patients who were RBC transfusion dependent at baseline and achieved transfusion independence on treatment, the median duration of RBC transfusion independence was 13.9 months in the azacitidine group and was not reached in the CCR group.</p><p>Of the patients in the azacitidine group who were platelet transfusion dependent at baseline, 40.6% (95% CI = 30.9, 50.8) of these patients became platelet transfusion independent during the treatment period, compared with 29.3% of (95% CI = 19.7, 40.4) patients in the combined CCR groups. In patients who were platelet transfusion dependent at baseline and achieved transfusion independence on treatment, the median duration of platelet transfusion independence was 10.8 months in the azacitidine group and 19.2 months in the CCR group.</p><p>Health- Related Quality of Life (HRQoL) was assessed using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). HRQoL data could be analysed for a subset of the full trial population. While there are limitations in the analysis, the available data suggest that patients do not experience meaningful deterioration in quality of life during treatment with azacitidine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Following subcutaneous administration of a single 75 mg/m<sup>2</sup> dose, azacitidine was rapidly absorbed with peak plasma concentrations of 750 &plusmn; 403 ng/ml occurring at 0.5 h after dosing (the first sampling point). The absolute bioavailability of azacitidine after subcutaneous relative to intravenous administration (single 75 mg/m<sup>2</sup> doses) was approximately 89% based on area under the curve (AUC).</p><p>Area under the curve and maximum plasma concentration (C<sub>max</sub>) of subcutaneous admiminstration of azacitidine were approximately proportional within the 25 to 100 mg/m<sup>2 </sup>dose range.</p><p><strong>Distribution</strong></p><p>Following intravenous administration, the mean volume of distribution was 76 &plusmn; 26 L, and systemic clearance was 147 &plusmn; 47 L/h.</p><p><strong>Biotransformation </strong></p><p>Based on <em>in vitro</em> data, azacitidine metabolism does not appear to be mediated by cytochrome P450 isoenzymes (CYPs), UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), and glutathione transferases (GSTs).</p><p>Azacitidine undergoes spontaneous hydrolysis and deamination mediated by cytidine deaminase. In human liver S9 fractions, formation of metabolites was independent of NADPH implying that azacitidine metabolism was not mediated by cytochrome P450 isoenzymes. An <em>in vitro </em>study of azacitidine with cultured human hepatocytes indicates that at concentrations of 1.0 &micro;M to 100 &micro;M (i.e. up to approximately 30-fold higher than clinically achievable concentrations), azacitidine does not induce CYP 1A2, 2C19, or 3A4 or 3A5. In studies to assess inhibition of a series of P450 isoenzymes (CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4) azacitidine up to 100 &mu;M did not produce inhibition. Therefore, CYP enzyme induction or inhibition by azacitidine at clinically achievable plasma concentrations is unlikely.</p><p><strong>Elimination</strong></p><p>Azacitidine is cleared rapidly from plasma with a mean elimination half-life (t<sub>&frac12;</sub>) after subcutaneous administration of 41 &plusmn; 8 minutes. No accumulation occurs after subcutaneous administration of 75 mg/m<sup>2</sup> azacitidine once daily for 7 days. Urinary excretion is the primary route of elimination of azacitidine and/or its metabolites. Following intravenous and subcutaneous administration of <sup>14</sup>C-azacitidine, 85 and 50% of the administered radioactivity was recovered in urine respectively, while &lt; 1% was recovered in faeces.</p><p><strong>Special populations</strong></p><p>The effects of hepatic impairment (see section 4.2), gender, age, or race on the pharmacokinetics of azacitidine have not been formally studied.</p><p><strong>Renal impairment </strong></p><p>Renal impairment has no major effect on the pharmacokinetic exposure of azacitidine after single and multiple subcutaneous administrations. Following subcutaneous administration of a single 75 mg/m<sup>2</sup> dose, mean exposure values (AUC and C<sub>max</sub>) from subjects with mild, moderate and severe renal impairment were increased by 11-21%, 15-27%, and 41-66%, respectively, compared to normal renal function subjects. However, exposure was within the same general range of exposures observed for subjects with normal renal function. Azacitidine can be administered to patients with renal impairment without initial dose adjustment provided these patients are monitored for toxicity since azacitidine and/or its metabolites are primarily excreted by the kidney.</p><p><strong>Pharmacogenomics</strong></p><p>The effect of known cytidine deaminase polymorphisms on azacitidine metabolism has not been formally investigated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azacitidine induces both gene mutations and chromosomal aberrations in bacterial and mammalian cell systems <em>in vitro</em>. The potential carcinogenicity of azacitidine was evaluated in mice and rats. Azacitidine induced tumours of the haematopoietic system in female mice, when administered intraperitoneally 3 times per week for 52 weeks. An increased incidence of tumours in the lymphoreticular system, lung, mammary gland, and skin was seen in mice treated with azacitidine administered intraperitoneally for 50 weeks. A tumorigenicity study in rats revealed an increased incidence of testicular tumours.</p><p>Early embryotoxicity studies in mice revealed a 44% frequency of intrauterine embryonal death (increased resorption) after a single intraperitoneal injection of azacitidine during organogenesis. Developmental abnormalities in the brain have been detected in mice given azacitidine on or before closure of the hard palate. In rats, azacitidine caused no adverse reactions when given pre-implantation, but it was clearly embryotoxic when given during organogenesis. Foetal abnormalities during organogenesis in rats included: CNS anomalies (exencephaly/encephalocele), limb anomalies (micromelia, club foot, syndactyly, oligodactyly) and others (microphthalmia, micrognathia, gastroschisis, oedema, and rib abnormalities).</p><p>Administration of azacitidine to male mice prior to mating with untreated female mice resulted in decreased fertility and loss of offspring during subsequent embryonic and postnatal development. Treatment of male rats resulted in decreased weight of the testes and epididymides, decreased sperm counts, decreased pregnancy rates, an increase in abnormal embryos and increased loss of embryos in mated females (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp; Mannitol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months. 
After reconstitution:
For subcutaneous use
When Zytedin is reconstituted using water for injections that has not been refrigerated, chemical and physical in-use stability of the reconstituted medicinal product has been demonstrated at 25°C for 1 hour and at 2 to 8°C for 8 hours.

The shelf life of the reconstituted medicinal product can be extended by reconstituting with refrigerated (2 to 8°C) water for injections. When Zytedin is reconstituted using refrigerated (2 to 8°C) water for injections, the chemical and physical in-use stability of the reconstituted medicinal product has been demonstrated at 2 to 8°C for 22 hours.
From a microbiological point of view, the reconstituted product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and must not be longer than 8 hours at 2 to 8°C when reconstituted using water for injections that has not been refrigerated or not longer than 22 hours when reconstituted using refrigerated (2 to 8°C) water for injections.   
For intravenous use
Zytedin reconstituted for intravenous administration may be stored at 25°C, but administration must be completed within 1 hour of reconstitution.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30ᵒC.</p><p>Store in the original package.</p><p><strong>Reconstituted suspension</strong></p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colourless glass vials sealed with bromobutyl rubber stoppers and flip-off caps.</p><p>Pack size: 1 Vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Recommendations for safe handling</strong></p><p>Zytedin is a cytotoxic medicinal product and, as with other potentially toxic compounds, caution should be exercised when handling and preparing azacitidine suspensions. Procedures for proper handling and disposal of anticancer medicinal products should be applied.</p><p>If reconstituted azacitidine comes into contact with the skin, immediately and thoroughly wash with soap and water. If it comes into contact with mucous membranes, flush thoroughly with water.</p><p><strong>Reconstitution procedure</strong></p><p><em>For subcutaneous use</em></p><p>Zytedin should be reconstituted with water for injections. The shelf life of the reconstituted medicinal product can be extended by reconstituting with refrigerated (2 to 8&deg;C) water for injections. Details on storage of the reconstituted product are provided below.</p><ol><li>The following supplies should be assembled: Vial(s) of azacitidine; vial(s) of water for injections; non-sterile surgical gloves; alcohol wipes; 5 ml injection syringe(s) with needle(s).</li><li>4 ml of water for injections should be drawn into the syringe, making sure to purge any air trapped within the syringe.</li><li>The needle of the syringe containing the 4 ml of water for injections should be inserted through the rubber top of the azacitidine vial followed by injection of the water for injections into the vial.</li><li>Following removal of the syringe and needle, the vial should be vigorously shaken until a uniform cloudy suspension is achieved. After reconstitution each ml of suspension will contain 25 mg of azacitidine (100 mg/4 ml). The reconstituted product is a homogeneous, cloudy suspension, free of agglomerates. The product should be discarded if it contains large particles or agglomerates. Do not filter the suspension after reconstitution since this could remove the active substance. It must be taken into account that filters are present in some adaptors, spikes and closed systems; therefore such systems should not be used for administration of the medicinal product after reconstitution.</li><li>The rubber top should be cleaned and a new syringe with needle inserted into the vial. The vial should then be turned upside down, making sure the needle tip is below the level of the liquid. The plunger should then be pulled back to withdraw the amount of medicinal product required for the proper dose, making sure to purge any air trapped within the syringe. The syringe with needle should then be removed from the vial and the needle disposed of.</li><li>A fresh subcutaneous needle (recommended 25-gauge) should then be firmly attached to the syringe. The needle should not be purged prior to injection, in order to reduce the incidence of local injection site reactions.</li><li>When more than 1 vial is needed all the above steps for preparation of the suspension should be repeated. For doses requiring more than 1 vial, the dose should be equally divided e.g., dose 150 mg = 6 ml, 2 syringes with 3 ml in each syringe. Due to retention in the vial and needle, it may not be feasible to withdraw all of the suspension from the vial.</li><li>The contents of the dosing syringe must be re-suspended immediately prior to administration. The syringe filled with reconstituted suspension should be allowed up to 30 minutes prior to administration to reach a temperature of approximately 20-25&deg;C. If the elapsed time is longer than 30 minutes, the suspension should be discarded appropriately and a new dose prepared. To re-suspend, vigorously roll the syringe between the palms until a uniform, cloudy suspension is achieved. The product should be discarded if it contains large particles or agglomerates.</li></ol><p><em>For intravenous use </em></p><p>Reconstitute the appropriate number of Zytedin vials to achieve the desired dose. Reconstitute each vial with 10 ml sterile water for injection. Vigorously shake or roll the vial until all solids are dissolved. The resulting solution will contain azacitidine 10 mg/ml. The solution should be clear. Parenteral drug product should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p><p>Withdraw the required amount of Zytedin solution to deliver the desired dose and inject into a 50-100 ml infusion bag of either 0.9% sodium chloride injection or lactated ringer&rsquo;s injection to obtain a final concentration of 1.8-3.6 mg/ml.</p><p>Zytedin is incompatible with 5% dextrose solutions, Hespan, or solutions that contain bicarbonate. These solutions have the potential to increase the rate of degradation of Zytedin and should therefore be avoided.</p><p><strong>Method of administration </strong></p><p><em>For subcutaneous use </em></p><p>Reconstituted Zytedin should be injected subcutaneously (insert the needle at a 45-90&deg; angle) using a 25-gauge needle into the upper arm, thigh or abdomen.</p><p>Doses greater than 4 ml should be injected into two separate sites.</p><p>Injection sites should be rotated. New injections should be given at least 2.5 cm from the previous site and never into areas where the site is tender, bruised, red, or hardened.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p><em>For intravenous use</em></p><p>Zytedin solution is administered intravenously. Administer the total dose over a period of 10-40 minutes. The administration must be completed within 1 hour of reconstitution of the Zytedin vial.</p><p><strong>Storage of the reconstituted product</strong></p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06 November 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>